Superworth

Orchestra BioMed revenue OBIO

Sales by quarter and over the last twelve months, from 2022.

Last 12 months, to Jun 30, 2026
$32M
Latest quarter, Q2 FY26
$88K
−89% on a year earlier
Fiscal year 2025
$33.5M
+1169% on the year before

Orchestra BioMed's revenue was $32M over the twelve months to Jun 30, 2026, up 986% on a year earlier.

In its latest quarter, Q2 FY26, it was $88K, down 89% on the same quarter a year before.

Revenue over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearRevenueChange
FY2025$33.5M+1169%
FY2024$2.6M−4%
FY2023$2.8M−22%
FY2022$3.5Mn/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedRevenueOn a year earlierLast 12 months
Q2 FY26$88K−89%$32M
Q1 FY26$110K−87%$32.7M
Q4 FY25$30.9M+12120%$33.5M
Q3 FY25$861K−13%$2.8M
Q2 FY25$836K+7%$2.9M
Q1 FY25$868K+40%$2.9M
Q4 FY24$253K−3%$2.6M
Q3 FY24$987K+136%$2.6M
Q2 FY24$778K−15%$2.1M
Q1 FY24$620K−47%$2.2M
Q4 FY23$262K−76%$2.8M
Q3 FY23$419K−64%$3.6M

Against its peers

Companies in Medical - Instruments & Supplies nearest Orchestra BioMed's size, closest first, today.

CompanyRevenue, 12 monthsGrowth
OBIOOrchestra BioMed$32M
EMBCEmbecta$1B−8% a year
INFUInfuSystem$143.3M+2% a year
UTMDUtah Medical Products$36.1M−7% a year
TCMDTactile Systems Technology$350.3M+17% a year
PDEXPro DEX$77.5M+16% a year
MDXGMimedx$355.2M−2% a year
MOVMovado$689.9M+5% a year
IRMDIradimed$86.3M+11% a year
STAAStaar Surgical$339.6M+51% a year
KEQUKewaunee Scientific$277.2M+5% a year
Peer median$308.4M

What the revenue tells you

Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.

Growing revenue with shrinking margins is a warning, not a win.

More on Orchestra BioMed

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.